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lead, CCRET has prospered and currently employs over 
70 staff in addition to visiting academics, students and 
trainees from across the world. In addition to his role at 
CCRET and at The Alfred Hospital, Henry was Consul-
tant Senior Director in Cardiovascular Trials at the high-
ly reputed George Institute for Global Health.
 Henry’s contribution to cardiovascular research is at-
tested to by his involvement with numerous major clini-
cal trials in which he served as the Principal Investigator 
and Chair or Member of data safety monitoring boards 
and executive committees. Many of these trials have in-
formed guidelines writing committees and health author-
ities, and have improved the practice of cardiovascular 
medicine as well as the lives of innumerable heart failure 
patients. He was Editor, Associate Editor and Editorial 
Board Member for many of the most prestigious journals 
in medicine and cardiology, and was an Editorial Board 
Member to  Cardiology for over a decade. Henry pub-
lished over 500 journal articles and numerous books and 
book chapters. 
 In a recent personal portray article in  The Lancet , Hen-
ry saw his most important contribution to cardiovascular 
science as his work on neurohormonal antagonists in 
heart failure, agents which were once contraindicated but 
today constitute the cornerstone of heart failure pharma-
cotherapy  [1, 2] . At CCRET, his research had a wide span 
and was truly translational. Henry undertook substantial 
 The global cardiovascular community is deeply sad-
dened by the recent passing of Prof. Henry Krum (Mon-
ash University, Melbourne, Australia) after a long illness. 
Henry was a highly valued colleague and friend, as well
as an extraordinary teacher, mentor and supervisor. His 
contributions to cardiovascular research have been pio-
neering and game changing. He was also a well-respected 
physician who was loved by his patients. Henry was Di-
rector of the Centre of Cardiovascular Research and Edu-
cation in Therapeutics (CCRET), and Chair of Medical 
Therapeutics at Monash University. He was also Head of 
the Department of Clinical Pharmacology at The Alfred 
Hospital, as well as Consultant Physician and Heart Fail-
ure Specialist at the Alfred Heart Centre, Melbourne. 
 Henry completed an MBBS at the University of Mel-
bourne in 1981. He became Fellow of the Royal Austral-
asian College of Physicians in 1989. Subsequently, he 
completed a PhD in Clinical Pharmacology at the Univer-
sity of Melbourne in 1991, and undertook a postdoctoral 
fellowship at Columbia University, New York. On return 
to Australia, he accepted the position of Head of the
Department of Clinical Pharmacology and was award-
ed a National Health and Medical Research Council 
(NHMRC) Centre of Clinical Research Excellence grant, 
with which he became the founding Director of CCRET, 
Monash University. He was promoted to Associate Pro-
fessor in 1997 and to full Professor in 2003. Under his 
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basic science studies, providing new mechanistic insights 
and producing therapeutic concepts which he subse-
quently evaluated in clinical trials. His recent work on 
aliskiren while serving as Global Principal Investigator of 
the ATMOSPHERE trial (recruiting over 7,000 patients), 
his landmark SYMPLICITY-HTN1 trial evaluating cath-
eter-based renal sympathetic denervation in hyperten-
sion, and his preclinical studies on cardiorenal syndrome 
and on angiotensin-receptor neprilysin inhibitors attest to 
the broad spectrum of highly successful research activities 
with which he was involved  [3–6] . Henry was also keen to 
get the best out of existing therapies, publishing clinically 
vital work on the impact of comorbidities on heart failure 
therapies, and being a founding member of the Beta-
Blockers in Heart Failure Collaborative Group  [7] .
 Among the many awards and prizes he won during his 
career are the NHMRC award for one of ‘Ten of the Best’ 
research projects in 2011 and the NHMRC Achievement 
Award of ‘Highest Ranked Practitioner Fellow 2011’. In 
2015 he was named on the Thomson Reuters Highly Cit-
ed Researchers list, ranking him among the top 1% most 
cited in his subject field and providing recognition as one 
of the most influential scientists in the world. Henry at-
tracted numerous major research prizes and grants dur-
ing his career, with funding by the Australian NHMRC, 
Cardiac Society of Australia and New Zealand, and oth-
ers. Among his most recent achievements, he secured an 
AUD 5.6 million NHMRC Program grant in 2015 dedi-
cated to chronic heart disease and comorbidities. 
 Henry had a genuinely innovative mind and happily 
discussed his thoughts and novel, sometimes unconven-
tional, ideas with colleagues. These discussions were 
fruitful and thought provoking for those in attendance. 
His breadth and depth of knowledge was unparalleled. He 
was an engaging speaker and captured the essence of sci-
entific matters with ease, be it at lab meetings or major 
international meetings. It only seemed logical that Henry 
founded the 4 Corners of Cardiology (4CC) meeting, held 
annually in Melbourne, which boasts a unique, highly in-
teractive format and became an immediate success. 
 Henry shared a passion for great coffee and great jazz 
music, as well as film and arts, and was a keen follower of 
sports, including soccer, tennis, rugby and cricket. He 
also loved the latest electronic gadgets such as smart-
phones, and once fell and broke his arm whilst sending a 
text message! His great sense of humor always shone 
through. Henry was a real gentleman with an easy-going 
manner who looked after his staff well, visiting fellows 
and trainees. Above all, he was a humble man, and his 
family meant everything to him. Henry is survived by his 
wife Lauren, his children Joshua and Emily, as well as his 
sister Sharon and extended family. His death is a tremen-
dous loss to the scientific world, and his legacy will con-
tinue to inspire colleagues, friends and the global cardio-
vascular community.
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